Pages that link to "Q33711127"
Jump to navigation
Jump to search
The following pages link to Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia (Q33711127):
Displaying 50 items.
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (Q24607479) (← links)
- Protein kinase inhibitors against malignant lymphoma (Q27024212) (← links)
- PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma (Q28256448) (← links)
- Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients (Q28291793) (← links)
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. (Q33392447) (← links)
- Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management (Q33395066) (← links)
- Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management (Q33400780) (← links)
- Waldenström macroglobulinemia: my way. (Q33402669) (← links)
- Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (Q33405096) (← links)
- Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management (Q33408517) (← links)
- Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (Q33414243) (← links)
- Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia (Q33414529) (← links)
- Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management (Q33421444) (← links)
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia (Q33429430) (← links)
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. (Q33437577) (← links)
- Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management (Q33438490) (← links)
- Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma (Q33439441) (← links)
- Targeted therapy in lymphoma (Q34413686) (← links)
- Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium (Q34488779) (← links)
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas (Q35525569) (← links)
- The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. (Q35859219) (← links)
- The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. (Q35911227) (← links)
- Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm (Q36064933) (← links)
- Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach (Q36494977) (← links)
- Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia (Q36533710) (← links)
- The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial (Q36734547) (← links)
- How to manage Waldenstrom's macroglobulinemia (Q36764811) (← links)
- Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities (Q37589551) (← links)
- New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma (Q37786616) (← links)
- Novel therapeutic agents for B-cell lymphoma: developing rational combinations (Q37803308) (← links)
- Novel treatment regimens for Waldenström's macroglobulinemia (Q37810101) (← links)
- Signal transduction inhibitor therapy for lymphoma (Q37829224) (← links)
- Emerging drugs for Waldenström's macroglobulinemia (Q37847176) (← links)
- Hematopoietic cell transplantation for Waldenström macroglobulinemia. (Q37875673) (← links)
- The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma (Q37877729) (← links)
- Utility of mTOR Inhibition in Hematologic Malignancies (Q37883723) (← links)
- Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique (Q37923308) (← links)
- Harnessing the cell death pathway for targeted cancer treatment (Q37942090) (← links)
- mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy (Q38004213) (← links)
- Research and innovation in the development of everolimus for oncology. (Q38014589) (← links)
- Molecular pathogenesis of Waldenstrom's macroglobulinemia. (Q38024773) (← links)
- Waldenström macroglobulinaemia: the key questions. (Q38104808) (← links)
- Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models (Q38150849) (← links)
- Signaling pathways in lymphoma: pathogenesis and therapeutic targets (Q38150876) (← links)
- Novel treatment options for Waldenström macroglobulinemia (Q38167433) (← links)
- Waldenström macroglobulinemia: from biology to treatment (Q38176969) (← links)
- The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy (Q38195885) (← links)
- Current and future therapeutic approach for Waldenström's macroglobulinemia (Q38206820) (← links)
- Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. (Q38212951) (← links)
- Genetic and molecular targets in lymphoma: implications for prognosis and treatment. (Q38294626) (← links)